Business
Why the Immutep (ASX:IMM) share price is up 6% today
The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company’s shares are up 5.97% to 36 cents.
New Phase 2b trial
The Immutep share price is on the move as investors have been rallying up on the positive news.
According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.
HNSCC is an aggressive life-threatening cancer that affects either the…
-
Business23 hours ago3 ASX 200 shares set to dominate the next decade
-
Business9 hours ago3 of the best ASX shares to buy with $5,000
-
General22 hours agoWife of missing pilot David Stephens says the experienced pilot had plane recently inspected
-
General14 hours agoFormer Russian President Dmitry Medvedev issues warning over Ukraine escalation